ICPT: AI 评分 51/100 — AI 分析 (4月 2026)

Intercept Pharmaceuticals, Inc. focuses on developing and commercializing therapies for progressive non-viral liver diseases. Its primary product, Ocaliva, treats primary biliary cholangitis, and the company is exploring Ocaliva's potential for nonalcoholic steatohepatitis and other liver conditions.

Key Facts: Price: $19.00 AI Score: 51/100 Sector: Healthcare

公司概况

概要：

Intercept Pharmaceuticals offers a focused investment opportunity in non-viral liver disease therapeutics, anchored by Ocaliva's established market presence for primary biliary cholangitis and potential expansion into the high-growth NASH market, boasting a strong 99.7% gross margin.

ICPT是做什么的？

Intercept Pharmaceuticals, incorporated in 2002 and headquartered in New York City, is a biopharmaceutical company dedicated to the discovery, development, and commercialization of innovative therapeutics for the treatment of progressive non-viral liver diseases. The company's flagship product, Ocaliva (obeticholic acid), a farnesoid X receptor (FXR) agonist, is approved for the treatment of primary biliary cholangitis (PBC) in combination with ursodeoxycholic acid (UDCA) in adults, or as monotherapy in adults unable to tolerate UDCA. Ocaliva represents a significant advancement in the management of PBC, a chronic and potentially life-threatening liver disease. Beyond PBC, Intercept is actively pursuing the development of Ocaliva for other liver diseases, most notably nonalcoholic steatohepatitis (NASH), a prevalent and rapidly growing liver condition with limited treatment options. The company's pipeline also includes other product candidates in various stages of clinical and preclinical development, reflecting its commitment to addressing unmet needs in liver disease. Intercept markets its products through an internal commercial organization and third-party distributors, ensuring broad access to its therapies in the United States, Europe, and Canada. The company also has a license agreement with Aralez Pharmaceuticals Canada Inc. to develop and commercialize bezafibrate in the United States.

ICPT的投资论点是什么？

Intercept Pharmaceuticals presents a notable market position driven by its established revenue stream from Ocaliva in PBC and the significant potential upside from its NASH program. The company's strong gross margin of 99.7% underscores the profitability of its core product. Successful development and approval of Ocaliva for NASH could unlock substantial value, given the large and underserved patient population. Intercept's focus on non-viral liver diseases positions it favorably in a market with increasing prevalence and limited therapeutic options. With a P/E ratio of 5.58, the company appears undervalued relative to its growth prospects, making it an attractive investment for those seeking exposure to the biopharmaceutical sector. Key catalysts include ongoing clinical trials for NASH and potential partnerships to expand its pipeline and market reach.

ICPT在哪个行业运营？

Intercept Pharmaceuticals operates within the biotechnology industry, specifically targeting the liver disease market. This market is characterized by increasing prevalence of conditions like NASH, driven by rising rates of obesity and diabetes. The competitive landscape includes companies like Albo, Aslan, CDMO, CMRX, and EXAI, all vying to develop and commercialize novel therapies for liver diseases. Intercept's focus on non-viral liver diseases and its established presence with Ocaliva in PBC position it favorably to capitalize on the growing demand for effective treatments. The NASH market, in particular, represents a significant growth opportunity, with projections estimating billions in potential revenue as effective therapies are approved.

Biotechnology

Healthcare

ICPT有哪些增长机遇？

NASH Market Expansion: The nonalcoholic steatohepatitis (NASH) market represents a substantial growth opportunity for Intercept. With no currently approved therapies, the potential market size is estimated to be in the billions of dollars. Intercept is actively developing Ocaliva for NASH, and positive clinical trial results could lead to regulatory approval and significant revenue growth. The timeline for potential approval is dependent on clinical trial outcomes, but analysts anticipate potential approval within the next 2-3 years.
Geographic Expansion: Intercept has the opportunity to expand its geographic reach beyond the United States, Europe, and Canada. Entering new markets, particularly in Asia and Latin America, could significantly increase the company's revenue base. The timeline for geographic expansion will depend on regulatory approvals and market access strategies in each new region. This expansion could potentially add millions in revenue over the next 3-5 years.
Pipeline Expansion: Intercept can expand its pipeline through internal research and development or through strategic acquisitions and licensing agreements. Developing new therapies for other liver diseases or expanding the indications for Ocaliva could drive future growth. The timeline for pipeline expansion is dependent on the success of research and development efforts and the availability of suitable acquisition targets. A diversified pipeline could significantly de-risk the company's growth prospects.
Combination Therapies: Intercept can explore the development of combination therapies that combine Ocaliva with other drugs to improve efficacy and address multiple aspects of liver disease. This approach could lead to more effective treatments and increased market share. The timeline for developing combination therapies will depend on clinical trial results and regulatory approvals. Combination therapies could potentially enhance the value proposition of Ocaliva and drive further revenue growth.
Lifecycle Management of Ocaliva: Intercept can extend the lifecycle of Ocaliva through various strategies, such as developing new formulations, expanding the indications, and conducting post-marketing studies to demonstrate long-term benefits. These efforts can help to maintain Ocaliva's market share and revenue stream over time. The timeline for lifecycle management activities is ongoing and continuous, ensuring the long-term value of the product.

Market Cap of $0.79B reflects the company's current valuation and growth potential in the liver disease therapeutics market.
P/E Ratio of 5.58 suggests the company may be undervalued relative to its earnings, indicating a potential investment opportunity.
Profit Margin of 40.3% demonstrates strong profitability and efficient operations.
Gross Margin of 99.7% highlights the high value and pricing power of Ocaliva.
Beta of 0.88 indicates lower volatility compared to the overall market, suggesting a relatively stable investment.

ICPT提供哪些产品和服务？

Develops and commercializes therapeutics for progressive non-viral liver diseases.
Markets Ocaliva for the treatment of primary biliary cholangitis (PBC).
Develops Ocaliva for nonalcoholic steatohepatitis (NASH).
Conducts clinical trials to evaluate the safety and efficacy of its product candidates.
Seeks regulatory approvals for its therapies in the United States, Europe, and Canada.
Markets its products through an internal commercial organization and third-party distributors.
Explores new indications and formulations for its existing products.

ICPT如何赚钱？

Develops and commercializes proprietary pharmaceutical products.
Generates revenue through the sale of Ocaliva.
Invests in research and development to expand its pipeline.
Partners with third-party distributors to reach a wider market.

Patients with primary biliary cholangitis (PBC).
Patients with nonalcoholic steatohepatitis (NASH).
Hospitals and clinics that treat liver diseases.
Specialty pharmacies that dispense Ocaliva.

Proprietary drug Ocaliva with established efficacy in PBC.
Strong intellectual property protection for its product candidates.
Specialized expertise in liver disease therapeutics.
Established relationships with key opinion leaders in hepatology.

什么因素可能推动ICPT股价上涨？

Upcoming: Clinical trial results for Ocaliva in NASH.
Upcoming: Potential regulatory approval of Ocaliva for NASH.
Ongoing: Expansion of Ocaliva's market share in PBC.
Ongoing: Development of new therapies for liver diseases.
Ongoing: Strategic partnerships and acquisitions.

ICPT的主要风险是什么？

Potential: Failure to obtain regulatory approval for NASH.
Potential: Competition from other companies developing NASH therapies.
Ongoing: Pricing pressures from payers.
Ongoing: Adverse events associated with Ocaliva.
Potential: Intellectual property challenges.

ICPT的核心优势是什么？

Established product with Ocaliva for PBC.
High gross margin of 99.7%.
Strong focus on non-viral liver diseases.
Experienced management team.

ICPT的劣势是什么？

Reliance on a single product for revenue.
Regulatory risks associated with drug development.
Competition in the NASH market.
Potential for generic competition in the future.

ICPT有哪些机遇？

Expansion into the NASH market.
Geographic expansion into new markets.
Development of new therapies for liver diseases.
Strategic partnerships and acquisitions.

ICPT面临哪些威胁？

Failure to obtain regulatory approval for NASH.
Competition from other companies developing NASH therapies.
Pricing pressures from payers.
Adverse events associated with Ocaliva.

ICPT的竞争对手是谁？

Albireo Pharma, Inc. — Focuses on developing and commercializing novel bile acid modulators. — (ALBO)
ASLAN Pharmaceuticals Limited — Develops novel therapeutics for inflammatory diseases. — (ASLN)
Avid Bioservices, Inc. — Contract development and manufacturing organization (CDMO) in the biotech space. — (CDMO)
Chimerix, Inc. — Develops and commercializes medicines to improve the lives of patients. — (CMRX)
Exact Sciences Corporation — Focuses on early cancer detection and prevention. — (EXAI)

Key Metrics

Price: $19.00 (+0.21%)
Market Cap: $794.7M
Volume: 3,906,002
MoonshotScore: 51/100

Company Profile

CEO: Jerome B. Durso
Headquarters: New York City, NY, US
Employees: 341
Founded: 2012

AI Insight

常见问题

What does Intercept Pharmaceuticals, Inc. do?

Intercept Pharmaceuticals is a biopharmaceutical company focused on developing and commercializing therapies for progressive non-viral liver diseases. Its primary product, Ocaliva, is approved for treating primary biliary cholangitis (PBC), a chronic liver disease. The company is also actively developing Ocaliva for nonalcoholic steatohepatitis (NASH), a more prevalent liver condition. Intercept's business model revolves around developing proprietary pharmaceutical products, generating revenue through sales, and investing in research and development to expand its pipeline and address unmet needs in the liver disease market.

Is ICPT stock a good buy?

ICPT stock presents a mixed investment profile. The company's strong gross margin of 99.7% and a P/E ratio of 5.58 suggest potential undervaluation. Successful development and approval of Ocaliva for NASH could significantly boost the stock price. However, the company's reliance on a single product and the regulatory risks associated with drug development are important considerations. Investors should carefully weigh the potential upside from NASH approval against the risks before investing.

What are the main risks for ICPT?

The main risks for Intercept Pharmaceuticals include the potential failure to obtain regulatory approval for Ocaliva in NASH, which would significantly impact its growth prospects. Competition from other companies developing NASH therapies also poses a threat. Pricing pressures from payers and the potential for adverse events associated with Ocaliva are additional risks. Furthermore, intellectual property challenges could impact the company's ability to protect its products and maintain its competitive advantage.